Response to: Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Noguchi et al

[...]it is only possible to say this in hindsight (ie, after it has been shown that different BTEs have distinct side effects rather than shared class side effects). Because little data preceded our report, we did not have adequate grounds to disregard class-effects a priori. [...]it is important to note that we present analyses restricted to individual BTEs precisely for this possibility. The fourth presented critique refers to the latter approval dates for certain BTEs rendering long-term follow-up impossible (because not enough time has passed since approval) for these BTE products. [...]adverse events occurring at longer follow-up periods will most likely be those that are reported with BTEs that have been approved for longer (namely blinatumomab).